Authors:
ROSEN TJ
COFFMAN KJ
MCLEAN S
CRAWFORD RT
BRYCE DK
GOHDA Y
TSUCHIYA M
NAGAHISA A
NAKANE M
LOWE JA
Citation: Tj. Rosen et al., SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF CP-122,721, A 2ND-GENERATION NK-1 RECEPTOR ANTAGONIST, Bioorganic & medicinal chemistry letters, 8(3), 1998, pp. 281-284
Authors:
LOWE JA
QIAN WM
MCLEAN S
BRYCE DK
CRAWFORD RT
OLSSON LC
BORDNER J
Citation: Ja. Lowe et al., DESIGN OF NOVEL CHOLECYSTOKININ-B RECEPTOR LIGANDS BASED ON THE DOUBLE-RING SYSTEM APPROACH, Regulatory peptides, 65(1), 1996, pp. 11-14
Authors:
MCLEAN S
GANONG A
SEYMOUR PA
BRYCE DK
CRAWFORD RT
MORRONE J
REYNOLDS LS
SCHMIDT AW
ZORN S
WATSON J
FOSSA A
DEPASQUALE M
ROSEN T
NAGAHISA A
TSUCHIYA M
HEYM J
Citation: S. Mclean et al., CHARACTERIZATION OF CP-122,721 - A NONPEPTIDE ANTAGONIST OF THE NEUROKININ NK1 RECEPTOR, The Journal of pharmacology and experimental therapeutics, 277(2), 1996, pp. 900-908
Authors:
HOWARD HR
SHENK KD
COFFMAN KC
BRYCE DK
CRAWFORD RT
MCLEAN SA
Citation: Hr. Howard et al., SYNTHESIS OF CONFORMATIONALLY RESTRICTED SUBSTANCE-P ANTAGONISTS, Bioorganic & medicinal chemistry letters, 5(2), 1995, pp. 111-114
Authors:
LOWE JA
HAGEMAN DL
DROZDA SE
MCLEAN S
BRYCE DK
CRAWFORD RT
ZORN S
MORRONE J
BORDNER J
Citation: Ja. Lowe et al., 5-PHENYL-3-UREIDOBENZAZEPIN-2-ONES AS CHOLECYSTOKININ-B RECEPTOR ANTAGONISTS, Journal of medicinal chemistry, 37(22), 1994, pp. 3789-3811
Authors:
LOWE JA
DROZDA SE
SNIDER RM
LONGO KP
ZORN SH
JACKSON ER
MORRONE J
MCLEAN S
BRYCE DK
BORDNER J
NAGAHISA A
KANAI Y
SUGA O
TSUCHIYA M
Citation: Ja. Lowe et al., DISCOVERY OF CP-96,345 AND ITS CHARACTERIZATION IN DISEASE-MODELS INVOLVING SUBSTANCE-P, Regulatory peptides, 46(1-2), 1993, pp. 20-23
Authors:
MCLEAN S
GANONG A
SEYMOUR PA
SNIDER RM
DESAI MC
ROSEN T
BRYCE DK
LONGO KP
REYNOLDS LS
ROBINSON G
SCHMIDT AW
SIOK C
HEYM J
Citation: S. Mclean et al., PHARMACOLOGY OF CP-99,994 - A NONPEPTIDE ANTAGONIST OF THE TACHYKININNEUROKININ-1 RECEPTOR, The Journal of pharmacology and experimental therapeutics, 267(1), 1993, pp. 472-479